IS6957A - Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim - Google Patents

Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim

Info

Publication number: IS6957A
Authority: IS; Iceland
Prior art keywords: triacetetracyclo; tatrate; pentaene; hexadecene; salts
Prior art date: 2001-05-14

Application number

IS6957A

Other languages

English (en)

Other versions

IS2217B (is

Inventor

Everett Bogle David

Robert Rose Peter

Robert Williams Glenn

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-14

Filing date

2003-09-15

Publication date

2003-09-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6957(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-09-15 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2003-09-15 Publication of IS6957A publication Critical patent/IS6957A/is

2007-03-15 Publication of IS2217B publication Critical patent/IS2217B/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Psychology (AREA)
Cardiology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
AIDS & HIV (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)

IS6957A 2001-05-14 2003-09-15 Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,8,-pentaeni. IS2217B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29086101P	2001-05-14	2001-05-14
PCT/IB2002/001437 WO2002092089A1 (en)	2001-05-14	2002-04-26	Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Publications (2)

Publication Number	Publication Date
IS6957A true IS6957A (is)	2003-09-15
IS2217B IS2217B (is)	2007-03-15

Family

ID=23117845

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6957A IS2217B (is)	2001-05-14	2003-09-15	Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,8,-pentaeni.

Country Status (47)

Country	Link
US (2)	US6890927B2 (is)
EP (1)	EP1392307B1 (is)
JP (1)	JP3779682B2 (is)
KR (1)	KR100551184B1 (is)
CN (1)	CN100370987C (is)
AP (1)	AP1473A (is)
AR (1)	AR033635A1 (is)
AT (1)	ATE302607T1 (is)
AU (1)	AU2002253482B2 (is)
BG (1)	BG66408B1 (is)
BR (1)	BR0209605A (is)
CA (1)	CA2447405C (is)
CR (1)	CR7080A (is)
CZ (1)	CZ304763B6 (is)
DE (1)	DE60205742T2 (is)
DK (1)	DK1392307T3 (is)
DO (1)	DOP2002000392A (is)
EA (1)	EA005528B1 (is)
EC (2)	ECSP034849A (is)
EE (1)	EE05441B1 (is)
EG (1)	EG24228A (is)
ES (1)	ES2246396T3 (is)
GE (1)	GEP20053712B (is)
GT (1)	GT200200084A (is)
HR (1)	HRP20030910B1 (is)
HU (1)	HU229867B1 (is)
IL (2)	IL157933A0 (is)
IS (1)	IS2217B (is)
MA (1)	MA27020A1 (is)
ME (1)	ME00466B (is)
MX (1)	MXPA03010364A (is)
MY (1)	MY127807A (is)
NO (1)	NO326148B1 (is)
NZ (1)	NZ528210A (is)
OA (1)	OA12599A (is)
PA (1)	PA8545101A1 (is)
PE (1)	PE20021065A1 (is)
PL (1)	PL214876B1 (is)
PT (1)	PT1392307E (is)
RS (1)	RS50814B (is)
SI (1)	SI1392307T1 (is)
SK (1)	SK287170B6 (is)
TN (1)	TNSN03113A1 (is)
TW (1)	TWI262078B (is)
UA (1)	UA73422C2 (is)
WO (1)	WO2002092089A1 (is)
ZA (1)	ZA200307235B (is)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1044189T4 (en) *	1997-12-31	2015-03-30	Pfizer Prod Inc	Aryl-fused fused azapolycyclic connections
AU2002351008B2 (en) *	2001-11-30	2007-07-12	Pfizer Products Inc.	Pharmaceutical compositions of 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
JP2006528237A (ja) *	2003-05-20	2006-12-14	ファイザー・プロダクツ・インク	バレニクリンの医薬組成物
EP1694686A1 (en) *	2003-12-19	2006-08-30	Takeda San Diego, Inc.	Kinase inhibitors
US20050250829A1 (en) *	2004-04-23	2005-11-10	Takeda San Diego, Inc.	Kinase inhibitors
CN1984903A (zh) *	2004-06-30	2007-06-20	伊莱利利公司	1－(吲哚－6－羰基－d－苯基甘氨酰基)－4－(1－甲基哌啶－4－基)哌嗪d－酒石酸盐
EP1778669A2 (en) *	2004-08-18	2007-05-02	Takeda San Diego, Inc.	Kinase inhibitors
CA2583101A1 (en) *	2004-10-15	2006-04-20	Pfizer Products Inc.	Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
DE602005023333D1 (de)	2004-10-15	2010-10-14	Takeda Pharmaceutical	Kinaseinhibitoren
KR20070098942A (ko) *	2005-02-24	2007-10-05	화이자 프로덕츠 인코포레이티드	고순도의 치환된 퀴녹살린의 제조 방법
US20110086086A1 (en) *	2005-07-26	2011-04-14	Pfizer Inc	Transdermal system for varenicline
US8119655B2 (en) *	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
EP1986994A2 (en) *	2006-02-21	2008-11-05	Teva Pharmaceutical Industries Ltd	Novel crystalline forms of armodafinil and preparation thereof
EA200970361A1 (ru)	2006-10-09	2010-02-26	Такеда Фармасьютикал Компани Лимитед	Ингибиторы киназы
EP2223925A1 (en) *	2006-10-09	2010-09-01	Takeda Pharmaceutical Company Limited	Kinase inhibitors
AU2007319951A1 (en) *	2006-11-09	2008-05-22	Pfizer Products Inc.	Polymorphs of nicotinic intermediates
US20090062257A1 (en) *	2007-08-29	2009-03-05	Protia, Llc	Deuterium-enriched varenicline
US20090105346A1 (en) *	2007-10-02	2009-04-23	Alexandr Jegorov	Novel crystalline forms of armodafinil and preparation thereof
US20090215787A1 (en) *	2008-02-22	2009-08-27	Mai De Ltd.	Preparations of new polymorphic forms of varenicline tartrate
WO2009111623A2 (en) *	2008-03-06	2009-09-11	Dr. Reddy's Laboratories Ltd.	Amorphous varenicline tartrate
US8440825B2 (en)	2008-03-06	2013-05-14	Medichem S.A.	Fumaric acid salt of varenicline
EP2271344A4 (en)	2008-03-31	2011-04-27	Univ South Florida	METHOD FOR TREATING ILLNESS-RELATED ATAXIA AND NON-ATTACHIC IMBALANCE
WO2009143347A2 (en) *	2008-05-22	2009-11-26	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) *	2008-05-26	2009-12-24	Glenmark	Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) *	2008-06-19	2009-12-23	Teva Pharmaceutical Industries Ltd.	Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) *	2008-07-10	2010-01-14	Revital Lifshitz-Liron	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) *	2008-09-01	2012-11-20	Actavis Group Ptc Ehf	Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
CA2801842A1 (en)	2009-06-10	2010-12-16	Actavis Group Ptc Ehf	Amorphous varenicline tartrate co-precipitates
WO2010151524A1 (en) *	2009-06-22	2010-12-29	Teva Pharmaceutical Industries Ltd	Solid states forms of varenicline salts and processes for preparation thereof
US20130101630A1 (en)	2010-03-09	2013-04-25	Actavis Group Ptc Ehf	Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
WO2011140431A1 (en)	2010-05-06	2011-11-10	Teva Pharmaceutical Industries Ltd.	Varenicline salts and crystal forms thereof
EP2837632B1 (en)	2012-04-13	2016-05-18	Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd.	Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases
KR101663550B1 (ko) *	2014-06-11	2016-10-07	조선대학교산학협력단	주석산을 유효성분으로 포함하는 고혈압 예방 또는 치료용 약학조성물 및 건강기능식품
KR101724301B1 (ko)	2016-11-22	2017-04-10	주식회사 한서켐	바레니클린 살리실산염의 i형 결정 및 그 제조방법
WO2018154395A2 (en)	2018-06-11	2018-08-30	Alvogen Malta Operations (Row) Ltd	Controlled release pharmaceutical composition of varenicline
EP4142734B1 (en)	2020-04-28	2025-08-20	Oyster Point Pharma, Inc.	Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
US20240374609A1 (en)	2021-08-20	2024-11-14	Viwit Pharmaceuticalco., Ltd.	Nitrosamine impurity, varenicline pharmaceutical composition capable of reducing generation of nitrosamine impurities and preparation and use thereof
KR20230068877A (ko)	2021-11-11	2023-05-18	주식회사 아울바이오	고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물
CN113980020B (zh) *	2021-11-22	2023-05-09	浙江车头制药股份有限公司	一种酒石酸伐尼克兰晶型的制备方法
US20250134904A1 (en)	2021-12-23	2025-05-01	Medichem, S.A.	Solid pharmaceutical formulations of varenicline
US11602537B2 (en)	2022-03-11	2023-03-14	Par Pharmaceutical, Inc.	Varenicline compound and process of manufacture thereof
EP4241775A1 (en)	2022-03-11	2023-09-13	Par Pharmaceutical, Inc.	Tablet comprising varenicline and process of preparation thereof
WO2023244574A1 (en)	2022-06-14	2023-12-21	Amygdala Neurosciences, Inc.	Aldh-2 inhibitor compounds and methods of use
EP4611896A1 (en)	2022-11-04	2025-09-10	Pfizer Inc.	Prodrugs of varenicline and compounds containing vulnerable amines
KR20240115109A (ko)	2023-01-18	2024-07-25	주식회사 아울바이오	고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학 조성물
IT202300003888A1 (it)	2023-03-03	2024-09-03	Dipharma Francis Srl	Processo di preparazione di un farmaco usato per trattare la dipendenza da nicotina
WO2024224270A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Varenicline formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3471503A (en)	1967-05-05	1969-10-07	Mcneilab Inc	1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
DK1044189T4 (en) *	1997-12-31	2015-03-30	Pfizer Prod Inc	Aryl-fused fused azapolycyclic connections
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
TWI236930B (en) *	2000-05-26	2005-08-01	Pfizer Prod Inc	Reactive crystallization method to improve particle size

2002
- 2002-04-26 EA EA200301121A patent/EA005528B1/ru active Protection Beyond IP Right Term
- 2002-04-26 AU AU2002253482A patent/AU2002253482B2/en not_active Expired
- 2002-04-26 ES ES02722625T patent/ES2246396T3/es not_active Expired - Lifetime
- 2002-04-26 MX MXPA03010364A patent/MXPA03010364A/es active IP Right Grant
- 2002-04-26 CA CA002447405A patent/CA2447405C/en not_active Expired - Lifetime
- 2002-04-26 SK SK1336-2003A patent/SK287170B6/sk not_active IP Right Cessation
- 2002-04-26 SI SI200230189T patent/SI1392307T1/sl unknown
- 2002-04-26 CZ CZ2003-2916A patent/CZ304763B6/cs not_active IP Right Cessation
- 2002-04-26 OA OA1200300289A patent/OA12599A/en unknown
- 2002-04-26 HU HU0304088A patent/HU229867B1/hu unknown
- 2002-04-26 DE DE60205742T patent/DE60205742T2/de not_active Expired - Lifetime
- 2002-04-26 CN CNB028099125A patent/CN100370987C/zh not_active Expired - Lifetime
- 2002-04-26 IL IL15793302A patent/IL157933A0/xx unknown
- 2002-04-26 WO PCT/IB2002/001437 patent/WO2002092089A1/en not_active Ceased
- 2002-04-26 EE EEP200300556A patent/EE05441B1/xx unknown
- 2002-04-26 ME MEP-2008-717A patent/ME00466B/me unknown
- 2002-04-26 HR HR20030910A patent/HRP20030910B1/xx not_active IP Right Cessation
- 2002-04-26 GE GE5341A patent/GEP20053712B/en unknown
- 2002-04-26 BR BR0209605-6A patent/BR0209605A/pt not_active IP Right Cessation
- 2002-04-26 UA UA20031110266A patent/UA73422C2/uk unknown
- 2002-04-26 AT AT02722625T patent/ATE302607T1/de active
- 2002-04-26 PL PL366551A patent/PL214876B1/pl unknown
- 2002-04-26 EP EP02722625A patent/EP1392307B1/en not_active Expired - Lifetime
- 2002-04-26 RS YUP-867/03A patent/RS50814B/sr unknown
- 2002-04-26 KR KR1020037014754A patent/KR100551184B1/ko not_active Expired - Lifetime
- 2002-04-26 PT PT02722625T patent/PT1392307E/pt unknown
- 2002-04-26 JP JP2002589006A patent/JP3779682B2/ja not_active Expired - Lifetime
- 2002-04-26 NZ NZ528210A patent/NZ528210A/en not_active IP Right Cessation
- 2002-04-26 DK DK02722625T patent/DK1392307T3/da active
- 2002-05-06 US US10/139,730 patent/US6890927B2/en not_active Expired - Lifetime
- 2002-05-06 DO DO2002000392A patent/DOP2002000392A/es unknown
- 2002-05-09 AP APAP/P/2002/002523A patent/AP1473A/en active
- 2002-05-10 PE PE2002000391A patent/PE20021065A1/es active IP Right Grant
- 2002-05-10 GT GT200200084A patent/GT200200084A/es unknown
- 2002-05-10 MY MYPI20021696A patent/MY127807A/en unknown
- 2002-05-13 TW TW091109919A patent/TWI262078B/zh not_active IP Right Cessation
- 2002-05-13 AR ARP020101734A patent/AR033635A1/es active IP Right Grant
- 2002-05-13 EG EG20020483A patent/EG24228A/xx active
- 2002-05-14 PA PA20028545101A patent/PA8545101A1/es unknown
2003
- 2003-07-08 TN TNPCT/IB2002/001437A patent/TNSN03113A1/fr unknown
- 2003-09-15 IS IS6957A patent/IS2217B/is unknown
- 2003-09-15 IL IL157933A patent/IL157933A/en active IP Right Grant
- 2003-09-16 ZA ZA200307235A patent/ZA200307235B/en unknown
- 2003-09-22 CR CR7080A patent/CR7080A/es not_active Application Discontinuation
- 2003-11-10 MA MA27389A patent/MA27020A1/fr unknown
- 2003-11-11 BG BG108343A patent/BG66408B1/bg unknown
- 2003-11-13 NO NO20035036A patent/NO326148B1/no not_active IP Right Cessation
- 2003-11-14 EC EC2003004849A patent/ECSP034849A/es unknown
- 2003-11-14 EC EC2003004850A patent/ECSP034850A/es unknown
2005
- 2005-02-28 US US11/069,724 patent/US7265119B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
MA27020A1 (fr)	2004-12-20
HUP0304088A2 (hu)	2004-04-28
EE200300556A (et)	2004-04-15
ECSP034850A (es)	2003-12-24
EP1392307B1 (en)	2005-08-24
IL157933A (en)	2013-07-31
KR20040010638A (ko)	2004-01-31
TNSN03113A1 (fr)	2005-12-23
SI1392307T1 (sl)	2005-12-31
CN1509174A (zh)	2004-06-30
EE05441B1 (et)	2011-08-15
HU229867B1 (en)	2014-10-28
ME00466B (me)	2011-10-10
EA005528B1 (ru)	2005-04-28
DE60205742D1 (de)	2005-09-29
PL366551A1 (en)	2005-02-07
CA2447405A1 (en)	2002-11-21
US20050148591A1 (en)	2005-07-07
BG66408B1 (bg)	2014-01-31
US20030166701A1 (en)	2003-09-04
HRP20030910B1 (hr)	2011-11-30
AP2002002523A0 (en)	2002-06-30
US6890927B2 (en)	2005-05-10
ES2246396T3 (es)	2006-02-16
CA2447405C (en)	2006-10-17
NO20035036L (no)	2003-11-13
DK1392307T3 (da)	2005-11-07
TWI262078B (en)	2006-09-21
PE20021065A1 (es)	2002-11-21
MY127807A (en)	2006-12-29
JP2004533446A (ja)	2004-11-04
PL214876B1 (pl)	2013-09-30
SK287170B6 (sk)	2010-02-08
SK13362003A3 (en)	2004-11-03
EG24228A (en)	2008-11-10
AU2002253482B2 (en)	2007-09-06
RS50814B (sr)	2010-08-31
HRP20030910A2 (en)	2004-02-29
DOP2002000392A (es)	2002-11-15
ZA200307235B (en)	2004-09-16
DE60205742T2 (de)	2006-05-11
PT1392307E (pt)	2005-11-30
GT200200084A (es)	2003-09-12
OA12599A (en)	2006-06-08
IS2217B (is)	2007-03-15
EA200301121A1 (ru)	2004-02-26
CR7080A (es)	2006-08-09
YU86703A (sh)	2006-05-25
WO2002092089A1 (en)	2002-11-21
CZ20032916A3 (cs)	2004-09-15
IL157933A0 (en)	2004-03-28
PA8545101A1 (es)	2003-09-05
US7265119B2 (en)	2007-09-04
AR033635A1 (es)	2003-12-26
EP1392307A1 (en)	2004-03-03
BG108343A (bg)	2004-12-30
CZ304763B6 (cs)	2014-10-01
JP3779682B2 (ja)	2006-05-31
GEP20053712B (en)	2005-12-26
AP1473A (en)	2005-09-30
NO20035036D0 (no)	2003-11-13
CN100370987C (zh)	2008-02-27
KR100551184B1 (ko)	2006-02-13
NO326148B1 (no)	2008-10-06
UA73422C2 (en)	2005-07-15
ECSP034849A (es)	2003-12-24
BR0209605A (pt)	2004-03-23
MXPA03010364A (es)	2004-03-16
NZ528210A (en)	2005-04-29
HK1062645A1 (en)	2004-11-19
HUP0304088A3 (en)	2011-11-28
ATE302607T1 (de)	2005-09-15

Publication	Publication Date	Title
IS6957A (is)	2003-09-15	Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim
NO2023030I1 (no)	2023-08-17	Apixaban and pharmaceutical acceptable salts thereof
NO20033566D0 (no)	2003-08-12	Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
NO20024175L (no)	2002-10-29	Azetidinderivater, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
FI20011478A0 (fi)	2001-07-05	Farmaseuttinen koostumus
NO20042739L (no)	2004-07-23	Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
NO20033556L (no)	2003-10-09	Farmasöytiske formuleringer
DE60203581D1 (de)	2005-05-12	Alfa-beta Titanlegierung
NO20040125L (no)	2004-01-12	Enterale formuleringer
NO20035298D0 (no)	2003-11-28	CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
DE60234409D1 (de)	2009-12-31	Säuregenerator, Sulfonsäure, Sulfonsäurederivate und strahlungsempfindliche Zusammensetzung
IT1318649B1 (it)	2003-08-27	Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
NO20042635L (no)	2004-06-23	5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
DK1417206T3 (da)	2010-08-16	Hidtil ukendte 2H-pyridazin-3-on-derivater, farmaceutiske præparater indeholdende det samme, og en fremgangsmåde til fremstilling af den aktive bestanddel
DE60209929D1 (de)	2006-05-11	Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
IS6956A (is)	2003-09-15	Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því
IS7051A (is)	2003-11-26	Lyfjasamsetningar
NO20040860L (no)	2004-04-22	Farmasoytisk sammensetning som innbefatter lumiracoxib
FI20022128L (fi)	2003-06-06	Farmaseuttinen koostumus
DK1373232T3 (da)	2006-03-27	Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner
DK1429753T3 (da)	2007-05-14	Farmaceutisk sammensætning omfattende gamma-butyrobetain
EE200300465A (et)	2003-12-15	Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
NO20031369L (no)	2003-05-22	Kalium-kanal interagerende forbindelser, og anvendelser derav
DK1235809T3 (da)	2004-03-15	Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazociner og deres anvendelse som lægemidler
DE50310743D1 (de)	2008-12-18	Wässrige formulierungen von (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4- trifluorbutan-1-sulfonat